Covid-19
New Study Shows Millions Saved by COVID Vaccination
COVID-19 vaccination saved an estimated 2.5 million lives, according to a new modeling study published in JAMA Health Forum.
AUGUST 8, 2025

CMS Updates COVID-19 Vaccination Reporting Requirements
Two COVID-19 vaccination reporting requirements have been removed by the CMS regarding Medicare payment policies and rates for inpatient rehabilitation facilities.
AUGUST 7, 2025

NCCN Guidelines Recommend mAbs for COVID-19 PrEP in People With Cancer
NCCN Guidelines for the Prevention and Treatment of Cancer-Related Infections advise clinicians recommend mAbs to protect against COVID-19.
AUGUST 5, 2025

Long Half-Life Seen With Novel mAb for COVID-19
The half life of the novel mAb candidate, VYD2311, may be six months or more.
JULY 8, 2025

Pemivibart Appears to Prevent COVID-19 Infection in CLL
Pemgarda is well tolerated and appears effective in preventing symptomatic COVID-19 infection among patients with chronic lymphocytic leukemia (CLL), who can be severely immunocompromised, according to a study reported at MAD-ID 2025.
JUNE 3, 2025

Ensitrelvir PEP Continues to Prevent SARS-CoV-2 Infection
If given within 72 hours after clinical onset of COVID-19 in a household, oral ensitrelvir was effective in protecting the household contacts from SARS-CoV-2 infection.
APRIL 17, 2025

Ensitrelvir Reduced the Risk for COVID-19 by 67%
Ensitrelvir, an antiretroviral being developed to prevent COVID-19, reduced the risk of developing the infection by 67% in uninfected people after exposure to SARS-CoV-2 compared with placebo at day 10.
MARCH 14, 2025

Pemgarda Neutralizing Activity Remains Stable Against Current Dominant SARS-CoV-2 Strain
Pemivibart, a next-generation COVID-19 monoclonal antibody (mAb), is still showing clinically meaningful in vitro neutralization data against the currently dominant LP.8.1 variant of SARS-CoV-2, according to data provided to the company by the FDA.
MARCH 7, 2025

RA Is a Risk Factor for Long COVID in older folks
Older adults are more susceptible to COVID-19 complications, especially those with pre-existing conditions such as rheumatoid arthritis.
SEPTEMBER 30, 2024

FDA Would Reduce Use of Pemgarda if It Becomes Less Effective
The FDA revised the EUA for the monoclonal antibody Pemgarda to limit its use if 90% or more of SARS CoV-2 variants are not susceptible to the drug.
AUGUST 28, 2024

FDA Approves/Authorizes Updated COVID-19 Vaccines; Target KP.2 Omicron Variant of SARS-CoV-2
The FDA approved and granted EUA for updated messenger RNA COVID-19 vaccines against the omicron variant KP.2 strain of SARS-CoV-2.
AUGUST 23, 2024

Federal Retail Pharmacy Program Crucial for COVID-19 Vaccination Efforts
The FRPP, a collaboration between the federal government, U.S. states and territories, and 21 national pharmacy chains and independent pharmacy networks, played a crucial role in administering bivalent COVID-19 vaccinations during the pandemic.
JULY 18, 2024
